Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
NLRP3/NALP3 Antibody (25N10E9) - BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody has been used in 1 publication
Supplier: Novus Biologicals NBP203948
Description
NLRP3/NALP3 Monoclonal specifically detects NLRP3/NALP3 in Human, Mouse samples. It is validated for Western Blot, Simple Western.Specifications
NLRP3/NALP3 | |
Monoclonal | |
1.0 mg/mL | |
Western Blot 2-5 ug/ml, Simple Western 1:50 | |
AII, AII/AVP, Angiotensin/vasopressin receptor AII/AVP-like, AVP, C1orf7, Caterpiller protein 1.1, CLR1.1, Cold autoinflammatory syndrome 1, Cold autoinflammatory syndrome 1 protein, Cryopyrin, Familial cold autoinflammatory syndrome, FCU, Leucine-rich repeat-, and PYD-containing protein 3, Muckle-Wells syndrome, MWS, NACHT, LRR and PYD containing protein 3, NACHT, LRR and PYD domains-containing protein 3, NALP3, NLR family, pyrin domain containing 3, NLRP3, NLRP3 monoclonal, Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat And Pyrin Domain Containing 3, PYPAF1, PYRIN-containing APAF1-like protein 1 | |
Mouse | |
Protein G purified | |
RUO | |
Primary | |
The epitope that 25N10E9 binds to the NOD region of NLRP3/NALP3 has not been mapped. | |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
IgG2b κ |
Western Blot | |
25N10E9 | |
Unconjugated | |
NP_001073289 | |
NLRP3 | |
A recombinant protein corresponding to the NOD domain of murine NLRP3/NALP3 Antibody (25N10E9) (amino acids 216-385) was used as the immunogen for this antibody. | |
0.1 mg | |
Alzheimers Research, Apoptosis, Cancer, Cardiovascular Biology, Cytokine Research, Immunology, Inflammation, Neurodegeneration, Signal Transduction | |
114548 | |
Human, Mouse | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction